Premium
Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma
Author(s) -
Nathanson Larry
Publication year - 2001
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20010301)91:5<881::aid-cncr1077>3.0.co;2-w
Subject(s) - medicine , adjuvant , melanoma , adjuvant therapy , clinical trial , clinical endpoint , malignancy , oncology , immunotherapy , adjuvant chemotherapy , chemotherapy , surgery , cancer , breast cancer , cancer research
Selected chemotherapy or immunotherapy agents with potential adjuvant activity in patients with melanoma may also reduce the risk of a second primary malignancy. Adjuvant trials employing such agents should be designed to prospectively record both adjuvant and risk reduction endpoints in the same patients.